‘Kovaxin’ can also be approved in India, expert panel recommends | Newsbaits

  • There is another great news for people battling the corona virus epidemic in India.

    The Subject Expert Committee (SEC) of the Corona Vaccine-linked Central Drugs Standard Control Organization (CDSCO) on Saturday recommended the India Biotak vaccine ‘covaxin’ to be approved for limited emergency use in the country.

    Earlier on Friday, the committee recommended approving the vaccine ‘Covishield’ prepared by AstraZeneca-Oxford University.

  • DCGI will give official approval for both vaccines

  • Explain that the SEC has sent applications to the Drug Controller General of India (DCGI) recommending the approval of emergency use of both the vaccines.

    Now both vaccines will be given official approval by DCGI. If this happens, India will get two vaccines simultaneously. ‘Kovaxin’ will be the country’s first vaccine in this.

    In such a situation, the eyes of crores of people of the country are now dependent on the decision of DCGI.

  • Bharat Biotech applied for approval on 8 December last

  • Hyderabad-based India biotech company is working on ‘Kovacsin’ in collaboration with the Indian Council of Medical Research (ICMR).

    The company applied for approval for the emergency use of the vaccine on December 8 after applying to Pfizer and Serum Institute.

    After examining the application, the SEC attached the company to the third stage trial and asked for data. He was made available to the company recently.

  • SEC terms regarding use of both vaccines

  • The SEC has conditionally approved the emergency use of AstraZeneca-Oxford’s ‘Kovishield’ and Bharat Biotech’s ‘Kovaxin’.

    The SEC has recommended the company approve limited emergency use of ‘covaxin’, and asked the company to expedite the recruitment of volunteers to complete the Phase III trial.

    In addition, ‘Kovishield’ is recommended to be used on people 18 years of age or older and a second dose in four to six weeks.

  • Not enough Volunteers for ‘Kovaxin’ Phase III Trial

    Not enough Volunteers for 'Kovaxin' Phase III Trial
  • At present, the biggest problem facing Bharat Biotech is the lack of adequate quantity of volunteers for Phase III trials.

    The company started the third phase of trials from November 20. For this, the company had targeted to give Kovaxin supplements to 25,800 volunteers in 20 research centers across the country.

    The highest of these were to be admitted to the 2,000-5,000 Volunteer Delhi AIIMS, but the required Volunteers have not yet arrived there.

  • “At least 60 percent vaccine will be effective”

  • Bharat Biotech’s head of quality operations Sai D Prasad said last month that the vaccine would prove to be at least 60 percent effective in preventing the corona virus. It can prove to be more effective when the final results of the third phase are out.

  • The country will get big relief with the approval

  • Approving limited emergency use of covaxin by India is considered a major step.

    The use of the vaccine can be expected to provide security to a country struggling with the threat of a new corona strain.

    Let me tell you that the new strain of corona found in the UK is said to be 70 percent more contagious and 33 cases have also been reported in India.

    The government is involved in sequencing the genome of all travelers from the UK.

  • Vaccination

    Vaccination can start across the country soon

  • With the approval of emergency use of both the vaccines, there is an increased hope of starting a vaccination campaign against Corona in the country. The government has already prepared for this.

    The government had earlier conducted a two-day dry run (rehearsal) on December 29 and 30 in eight districts of Assam, Gujarat, Andhra Pradesh and Punjab.

    After this, on Saturday too, a dry run has been organized in 259 places in 116 districts across the country.

  • Source link